| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |